| Visalia Family Practice Medical Group | |
|
107 N Hall St Ste D Visalia CA 93291-5850 | |
| (559) 625-9200 | |
| (559) 625-0665 |
| Full Name | Visalia Family Practice Medical Group |
|---|---|
| Speciality | Family Medicine |
| Location | 107 N Hall St Ste D, Visalia, California |
| Authorized Official Name and Position | Breana Bergdorf (ADMINISTRATOR) |
| Authorized Official Contact | 5596259200 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Visalia Family Practice Medical Group 107 N Hall St Ste D Visalia CA 93291-5850 Ph: (559) 625-9200 | Visalia Family Practice Medical Group 107 N Hall St Ste D Visalia CA 93291-5850 Ph: (559) 625-9200 |
| NPI Number | 1073681730 |
|---|---|
| Provider Enumeration Date | 12/01/2006 |
| Last Update Date | 01/05/2023 |
| Medicare PECOS PAC ID | 9830139179 |
|---|---|
| Medicare Enrollment ID | O20050505001220 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073681730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Elizabeth M Sasaki |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801829411 PECOS PAC ID: 3678465457 Enrollment ID: I20040326000544 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Paul J Schommer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730163064 PECOS PAC ID: 6709890486 Enrollment ID: I20080502000172 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | John C Booker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790769768 PECOS PAC ID: 3971517657 Enrollment ID: I20080505000700 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Thomas E Daglish |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982688206 PECOS PAC ID: 4981618667 Enrollment ID: I20080512000756 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Mark V Tetz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891779138 PECOS PAC ID: 1254345937 Enrollment ID: I20080513000239 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Edgar H Clark |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003847872 PECOS PAC ID: 8628159829 Enrollment ID: I20080516000693 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Christopher J Rodarte |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053383091 PECOS PAC ID: 3678644507 Enrollment ID: I20080723000746 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Laurie Hagopian-dresser |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578513610 PECOS PAC ID: 9638201833 Enrollment ID: I20100723000748 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Maria Yepiz-wang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174927214 PECOS PAC ID: 4587961438 Enrollment ID: I20160321002177 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Monica M Joosten |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750916094 PECOS PAC ID: 6709215296 Enrollment ID: I20200403002993 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
| Provider Name | Violetta Suleymanova |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215469226 PECOS PAC ID: 3971923046 Enrollment ID: I20201012002785 |
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
News Archive
This study examined Medicare data on beneficiaries diagnosed with colorectal cancer between 1995 and 2005 who ranged from 67 to 85 years old. The authors found, "Medicare beneficiaries with colon cancer had better outcomes if they had more primary care utilization before diagnosis. Even within this universally insured population, 28% of Medicare beneficiaries with colon cancer had no or only 1 contact with primary care physicians in the 3 to 27 months before the diagnosis.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).
One little understood paradox in the study of obesity is that overweight people who break down fat at a high rate are less healthy than peers who store their fat more effectively.
› Verified 9 days ago
Wei Tzuoh Chen Md Facp A Professional Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 431 S Bridge Street, Visalia, CA 93277 Phone: 559-732-4662 Fax: 559-636-2733 | |
Compassionate Family Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 306 N Conyer St, Visalia, CA 93291 Phone: 559-713-1101 Fax: 559-713-1121 | |
Oakview Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1011 N. Demaree St., Visalia, CA 93291 Phone: 559-734-6700 Fax: 559-734-6705 | |
San Joaquin Prime Care Medical Group Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 536 N Court St, Visalia, CA 93291 Phone: 559-592-2134 | |
Premier Walk-in Medical, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4025 W Caldwell Ave, Suite A, Visalia, CA 93277 Phone: 559-625-6080 Fax: 559-625-6024 | |
Premier Walk-in Medical Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4025 W Caldwell Ave, Suite A, Visalia, CA 93277 Phone: 559-733-4505 Fax: 559-733-0876 | |
County Of Tulare Health And Human Services Agency Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2505 N. Dinuba Blvd., Visalia, CA 93291 Phone: 559-624-8000 |